Cargando…

Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection

BACKGROUND: Middle East respiratory syndrome coronavirus (MERS-CoV), a new coronavirus that emerged in 2012, causes severe and fatal acute respiratory illness in man. Its high mortality (roughly 38%) has raised public fear worldwide, calling for the development of effective and safe therapeutics to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Shibo, Tao, Xinrong, Xia, Shuai, Garron, Tania, Yu, Fei, Du, Lanying, Lu, Lu, Tseng, Chien-Te K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159274/ http://dx.doi.org/10.1016/S0140-6736(15)00625-X

Ejemplares similares

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2016)

Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV
por: Jiang, Yuting, et al.
Publicado: (2018)

The characteristics of hDPP4 transgenic mice subjected to aerosol MERS coronavirus infection via an animal nose‐only exposure device
por: Hao, Xin‐yan, et al.
Publicado: (2019)

Complement Receptor C5aR1 Inhibition Reduces Pyroptosis in hDPP4-Transgenic Mice Infected with MERS-CoV
por: Jiang, Yuting, et al.
Publicado: (2019)

Elevated Human Dipeptidyl Peptidase 4 Expression Reduces the Susceptibility of hDPP4 Transgenic Mice to Middle East Respiratory Syndrome Coronavirus Infection and Disease
por: Algaissi, Abdullah, et al.
Publicado: (2019)

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines
por: Ma, Cuiqing, et al.
Publicado: (2014)

Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection
por: Channappanavar, Rudragouda, et al.
Publicado: (2015)

Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus
por: Tang, Jian, et al.
Publicado: (2015)

Middle East Respiratory Syndrome-Coronavirus Infection into Established hDPP4-Transgenic Mice Accelerates Lung Damage Via Activation of the Pro-Inflammatory Response and Pulmonary Fibrosis
por: Kim, Ju, et al.
Publicado: (2020)

A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2013)

Correction: A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2022)

Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design
por: Ma, Cuiqing, et al.
Publicado: (2014)

Calling for rapid development of a safe and effective MERS vaccine
por: Hotez, Peter J., et al.
Publicado: (2014)

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus
por: Zhang, Naru, et al.
Publicado: (2016)

Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines
por: Du, Lanying, et al.
Publicado: (2016)

Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection
por: Agrawal, Anurodh Shankar, et al.
Publicado: (2016)

Isolation of MERS-related coronavirus from lesser bamboo bats that uses DPP4 and infects human-DPP4-transgenic mice
por: Lau, Susanna K. P., et al.
Publicado: (2021)

Receptor-binding domain-based subunit vaccines against MERS-CoV
por: Zhang, Naru, et al.
Publicado: (2015)

A Human DPP4-Knockin Mouse’s Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV
por: Fan, Changfa, et al.
Publicado: (2018)

Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread
por: Lu, Lu, et al.
Publicado: (2013)

Vaccines for the prevention against the threat of MERS-CoV
por: Du, Lanying, et al.
Publicado: (2016)

Current advancements and potential strategies in the development of MERS-CoV vaccines
por: Zhang, Naru, et al.
Publicado: (2014)

Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein
por: Xia, Shuai, et al.
Publicado: (2014)

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
por: Xia, Shuai, et al.
Publicado: (2019)

DPP4-directed therapeutic strategies for MERS-CoV
por: Reinhold, Dirk, et al.
Publicado: (2014)

MERS-CoV infection causes brain damage in human DPP4-transgenic mice through complement-mediated inflammation
por: Jiang, Yuting, et al.
Publicado: (2021)

Pharmacokinetics of Intranasally Administered Dexmedetomidine in Chinese Children
por: Wang, Cheng-Yu, et al.
Publicado: (2019)

Development of a recombinant vaccine containing a spike S1-Fc fusion protein induced protection against MERS-CoV in human DPP4 knockin transgenic mice
por: Jung, Bo-Kyoung, et al.
Publicado: (2022)

Adaptive Evolution of MERS-CoV to Species Variation in DPP4
por: Letko, Michael, et al.
Publicado: (2018)

Safety and Pharmacokinetics of Intranasally Administered Heparin
por: Harris, Hannah M., et al.
Publicado: (2022)

Safety and Pharmacokinetics of Intranasally Administered Heparin
por: Harris, Hannah M., et al.
Publicado: (2022)

Intranasal Administration of Maleic Anhydride-Modified Human Serum Albumin for Pre-Exposure Prophylaxis of Respiratory Syncytial Virus Infection
por: Sun, Zhiwu, et al.
Publicado: (2015)

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain
por: Zhou, Yusen, et al.
Publicado: (2019)

Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD
por: Wang, Cong, et al.
Publicado: (2019)

Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen
por: Nyon, Mun Peak, et al.
Publicado: (2018)

Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus
por: Agrawal, Anurodh Shankar, et al.
Publicado: (2016)

Intranasal application of polyethyleneimine suppresses influenza virus infection in mice
por: He, Biao, et al.
Publicado: (2016)

Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4
por: Xia, Shuai, et al.
Publicado: (2019)

Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS)
por: Lu, Lu, et al.
Publicado: (2015)

Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model
por: Munster, Vincent J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_httji6m26ckj9pc050v4rsecv7